Although a watchful waiting approach to rectal cancer surgery is associated with a high rate of rectal preservation among patients who achieve a clinical complete response after neoadjuvant therapy, it may adversely affect survival and also distant control in certain patients, suggests data from a case series.
Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.
Two meta-analyses published in the Journal of Viral Hepatitis confirm that patients with hepatitis B virus infection remain at risk for hepatocellular carcinoma even after achieving positive virologic outcomes, and identify factors associated with the risk.
More than 290 million people, or 3.9% of the global population, are infected with hepatitis B virus, and while efforts to combat infection are improving, greater access to diagnosis and treatment is needed to meet global targets, report The Polaris Observatory Collaborators.
The American Association for the Study of Liver Diseases has issued a guidance statement for chronic hepatitis B virus, covering topics ranging from screening and prevention through to the clinical management of patients.
Caucasian patients with chronic hepatitis B virus infection who receive long-term therapy with tenofovir disoproxil fumarate or entecavir have “excellent” survival, which is comparable to that of the general population, say researchers.
The noninvasive fibrosis-4 index can further refine the existing favorable clinical profile for hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B virus infection and help identify those with the lowest risk, say researchers.
Serum hepatitis B virus RNA levels correlate with viral transcriptional activity and histologic changes in the livers of patients with chronic HBV who are receiving nucleos(t)ide analog therapy, Chinese researchers report.
Most patients with chronic hepatitis B virus infection initially classed as partial responders to treatment with tenofovir disoproxil fumarate achieve a virologic response without additional treatment adjustment, research suggests.
Being in the immune tolerant phase of chronic hepatitis B virus (HBV) infection is no assurance against the risk for developing hepatocellular carcinoma (HCC), requiring liver transplantation, or dying, say South Korean investigators.